Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. (BJDX) priced its initial public offering on Nov 12, 2021 at $10.00 per share, raising $21.6M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $126.9M. Dawson James was lead-left underwriter. Schiff Hardin advised the company and Ellenoff Grossman & Schole advised the underwriters.

Bluejay Diagnostics, Inc. is a late-stage, pre-revenue company developing a rapid near-patient diagnostic system, Symphony, for triage, diagnosis and monitoring of disease progression. It consists of a small instrument and single-use test cartridges and awaits FDA clearance.

Status

IPO

Ticker

BJDX

Exchange

Nasdaq Capital Market

Priced

Nov 12, 2021

IPO price

$10.00

Raised

$21.6M

Market cap at IPO price

$126.9M

First filed

Oct 4, 2021

Underwriters

Dawson James

Company counsel

Schiff Hardin

Underwriters' counsel

Ellenoff Grossman & Schole

Sector

Healthcare

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.